Julie Reisinger

Julie Reisinger

Auto-generated profile, based on publicly available information

Julie Reisinger

Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2018 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SKStephen B. Keysar
Stephen B. Keysar
JEJustin R. Eagles
Justin R. Eagles
BMBettina Miller
Bettina Miller
BJBrian C. Jackson
Brian C. Jackson
FCFarshad N. Chowdhury
Farshad N. Chowdhury
AJAntonio Jimeno
Antonio Jimeno
Purpose: Salivary gland cancers (SGC) frequently present with distant metastases many years after diagnosis, suggesting a cancer stem cell (CSC) subpopulation that initiates late recurrences; however, current models are limited both in their availability and suitability to characterize these rare cells. Experimental Design: Patient-derived xenografts (PDX) were generated by engrafting patient tissue onto nude mice from one acinic cell carcinoma (AciCC), four adenoid cystic carcinoma (ACC), and three mucoepidermoid carcinoma (MEC) cases, which were derived from successive relapses from the same MEC patient. Patient and PDX samples were analyzed by RNA-seq and Exome-seq. Sphere formation potential and in vivo tumorigenicity was assessed by sorting for Aldefluor (ALDH) activity and CD44-expressing subpopulations. Results: For successive MEC relapses we found a time-dependent increase in CSCs (ALDH+CD44high), increasing from 0.2% to 4.5% (P=0.033), but more importantly we observed an increase in individual CSC sphere formation and tumorigenic potential. A 50% increase in mutational burden was documented in subsequent MEC tumors, and this was associated with increased expression of tumor-promoting genes (MT1E, LGR5, and LEF1), decreased expression of tumor-suppressor genes (CDKN2B, SIK1, and TP53), and higher expression of CSC-related proteins such as SOX2, MYC, and ALDH1A1. Finally, genomic analyses identified a novel NFIB–MTFR2 fusion in an ACC tumor and confirmed previously reported fusions (NTRK3–ETV6 and MYB–NFIB). Conclusions: Sequential MEC PDX models preserved key patient features and enabled the identification of genetic events putatively contributing to increases in both CSC proportion and intrinsic tumorigenicity, which mirrored the patient's clinical course. Clin Cancer Res; 24(12); 2935–43. ©2018 AACR.

1 March 2020 in Cancer Research
Verified
Journal Article
Open access
PDF file
SKStephen B. Keysar
Stephen B. Keysar
NGNathan Gomes
Nathan Gomes
BMBettina Miller
Bettina Miller
BJBrian C. Jackson
Brian C. Jackson
PLPhuong N. Le
Phuong N. Le
AJAntonio Jimeno
Antonio Jimeno
Cancer stem cells (CSC) drive growth, therapy resistance, and recurrence in head and neck squamous cell carcinoma (HNSCC). Regulation of protein translation is crucial for normal stem cells and CSCs; its inhibition could disrupt stemness properties, but translation inhibitors are limited clinically due to toxicity. SVC112 is a synthetic derivative of bouvardin, a plant-derived translation elongation inhibitor. SVC112 had greater antiproliferative effects on HNSCC cells compared with the FDA-approved translation inhibitor omacetaxine mepesuccinate (HHT). SVC112 preferentially inhibited cancer cells compared with patient-matched cancer-associated fibroblasts, whereas HHT was equally toxic to both. SVC112 reduced sphere formation by cell lines and CSCs. SVC112 alone inhibited the growth of patient-derived xenografts (PDX), and SVC112 combined with radiation resulted in tumor regression in HPV-positive and HPV-negative HNSCC PDXs. Notably, CSC depletion after SVC112 correlated with tumor response. SVC112 preferentially impeded ribosomal processing of mRNAs critical for stress response and decreased CSC-related proteins including Myc and Sox2. SVC112 increased cell-cycle progression delay and slowed DNA repair following radiation, enhancing colony and sphere formation radiation effects. In summary, these data demonstrate that SVC112 suppresses CSC-related proteins, enhances the effects of radiation, and blocks growth of HNSCC PDXs by inhibiting CSCs. Significance: Inhibiting protein elongation with SVC112 reduces tumor growth in head and neck squamous cell carcinoma and increases the effects of radiation by targeting the cancer stem cell pool.

21 October 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
JMJ. Jason Morton
J. Jason Morton
NANathaniel Alzofon
Nathaniel Alzofon
SKStephen B. Keysar
Stephen B. Keysar
TCTugs-Saikhan Chimed
Tugs-Saikhan Chimed
JRJulie Reisinger
Julie Reisinger
AJAntonio Jimeno
Antonio Jimeno
Resistance to immunotherapy is a significant challenge, and the scarcity of human models hinders the identification of the underlying mechanisms. To address this limitation, we constructed an autologous humanized mouse (aHM) model with hematopoietic stem and progenitor cells (HSPC) and tumors from 2 melanoma patients progressing to immunotherapy. Unlike mismatched humanized mouse (mHM) models, generated from cord blood–derived HSPCs and tumors from different donors, the aHM recapitulates a patient-specific tumor microenvironment (TME). When patient tumors were implanted on aHM, mHM, and NOD/SCID/IL2rg−/− (NSG) cohorts, tumors appeared earlier and grew faster on NSG and mHM cohorts. We observed that immune cells differentiating in the aHM were relatively more capable of circulating peripherally, invading into tumors and interacting with the TME. A heterologous, human leukocyte antigen (HLA-A) matched cohort also yielded slower growing tumors than non–HLA-matched mHM, indicating that a less permissive immune environment inhibits tumor progression. When the aHM, mHM, and NSG cohorts were treated with immunotherapies mirroring what the originating patients received, tumor growth in the aHM accelerated, similar to the progression observed in the patients. This rapid growth was associated with decreased immune cell infiltration, reduced interferon gamma (IFNγ)–related gene expression, and a reduction in STAT3 phosphorylation, events that were replicated in vitro using tumor-derived cell lines. Implications: Engrafted adult HSPCs give rise to more tumor infiltrative immune cells, increased HLA matching leads to slower tumor initiation and growth, and continuing immunotherapy past progression can paradoxically lead to increased growth.

31 March 2023
Verified
Other
Open access
SKStephen B. Keysar
Stephen B. Keysar
NGNathan Gomes
Nathan Gomes
BMBettina Miller
Bettina Miller
BJBrian C. Jackson
Brian C. Jackson
PLPhuong N. Le
Phuong N. Le
AJAntonio Jimeno
Antonio Jimeno
Cancer stem cells (CSC) drive growth, therapy resistance, and recurrence in head and neck squamous cell carcinoma (HNSCC). Regulation of protein translation is crucial for normal stem cells and CSCs; its inhibition could disrupt stemness properties, but translation inhibitors are limited clinically due to toxicity. SVC112 is a synthetic derivative of bouvardin, a plant-derived translation elongation inhibitor. SVC112 had greater antiproliferative effects on HNSCC cells compared with the FDA-approved translation inhibitor omacetaxine mepesuccinate (HHT). SVC112 preferentially inhibited cancer cells compared with patient-matched cancer-associated fibroblasts, whereas HHT was equally toxic to both. SVC112 reduced sphere formation by cell lines and CSCs. SVC112 alone inhibited the growth of patient-derived xenografts (PDX), and SVC112 combined with radiation resulted in tumor regression in HPV-positive and HPV-negative HNSCC PDXs. Notably, CSC depletion after SVC112 correlated with tumor response. SVC112 preferentially impeded ribosomal processing of mRNAs critical for stress response and decreased CSC-related proteins including Myc and Sox2. SVC112 increased cell-cycle progression delay and slowed DNA repair following radiation, enhancing colony and sphere formation radiation effects. In summary, these data demonstrate that SVC112 suppresses CSC-related proteins, enhances the effects of radiation, and blocks growth of HNSCC PDXs by inhibiting CSCs.Significance:Inhibiting protein elongation with SVC112 reduces tumor growth in head and neck squamous cell carcinoma and increases the effects of radiation by targeting the cancer stem cell pool.

31 March 2023
Verified
Other
Open access
SKStephen B. Keysar
Stephen B. Keysar
JEJustin R. Eagles
Justin R. Eagles
BMBettina Miller
Bettina Miller
BJBrian C. Jackson
Brian C. Jackson
FCFarshad N. Chowdhury
Farshad N. Chowdhury
AJAntonio Jimeno
Antonio Jimeno
Fig. S4. Significantly enriched biological processes. Multiple biological pathways were differentially enriched in F1 vs. F0 and F2 vs. F0 comparisons. FDR adjusted p-values are represented by bubble color, while bubble size represents relative gene set sizes. The axes are not intrinsically meaningful, but simply serve to group similar GO terms more closely. (A) Biological processes enriched for downregulated genes in F1 vs. F0 comparisons. (B) Biological processes enriched for upregulated genes in F1 vs. F0 comparisons. (C) Biological processes enriched for downregulated genes in F2 vs. F0 comparisons. (D) Biological processes enriched for upregulated genes in F2 vs. F0 comparisons. the regulation of the immune response biological process was most significantly enriched for downregulated genes in both PDX generations when compared to F0 samples. Similarly, processes involving cytokine and leukocyte activity were also significantly downregulated, while epidermis development and keratinocyte-related processes were significantly enriched in PDX tumors.

31 March 2023
Verified
Other
Open access
SKStephen B. Keysar
Stephen B. Keysar
JEJustin R. Eagles
Justin R. Eagles
BMBettina Miller
Bettina Miller
BJBrian C. Jackson
Brian C. Jackson
FCFarshad N. Chowdhury
Farshad N. Chowdhury
AJAntonio Jimeno
Antonio Jimeno
Excel file containing deferentially expressed genes (RNA-seq) for comparisons of CUSG006, -007, and -012 tumors.